ICU Stay and Mortality Between Vaccinated and Non-Vaccinated Patients of Covid-19; A comparative Study

Abstract

Objective: The aim of this study is to compare the ICU stay and mortality in vaccinated and non-vaccinated covid-19 patients. Study Design: A Retrospective/ Comparative study Place and Duration: The study was conducted in Medicine department of Fauji Foundation Hospital Rawalpindi, duration of six months from October 2020 to March 2021. Methods: Total 120 patients of both genders had coronavirus disease were presented in this study. Patients were aged between 22-80 years. Demographical details of patients including age, sex, body mass index, residency and socio-economic status were recorded after taking informed written consent. Patients were admitted in COVID 19 ward. Chest X-rays of both groups were taken. There were 50 vaccinated patients in group I and 70 non-vaccinated patients in group II. Co-morbidities among both groups were assessed. Recovery and outcomes among both groups were calculated in terms of mortality and reduction in severity of disease. Complete data was analyzed by SPSS 24.0 version. Results: There were 80 (66.7%) patients were males (35 in group I and 45 in group II) and 40 (33.3%) were females (15 in group I and 25 in group II). Mean age of the vaccinated patients was 46.21 ±9.67 years with mean BMI 32.12 ±6.33 kg/m2 and in group II mean age was 45.13 ±21.54 years with mean BMI 33.11±11.37 kg/m2. 34 (68%) were educated in group I and in group II 35 (50%) patients were literate. Severity of disease among non-vaccinated patients was high found in 55 (78.6%) cases as compared to vaccinated cases 17 (34%). Co-morbidities were diabetes mellitus, hypertension, ischaemic heart and chronic lung disease. Most of the patients 90 (75%) had bilateral lung involvement and interstitial infiltrates 105 (87.5%). Fever, cough and dyspnea were the most common symptom found in both groups. Recovery among patients of group I was greater 40 (80%) as compared to non-vaccinated 27 (38.6%). Frequency of poor outcomes hospitalization 9 (12.9%), ICU admission 11 (15.8%) and mortality 23 (32.9%) among non-vaccinated patients were significantly higher as compared to vaccinated patients in which hospitalization 2 (4%), ICU admission 3 (6%) and mortality was found in 5 (10%) cases. Conclusion: According to the findings of this study, vaccination against coronavirus disease is both efficacious and beneficial in reducing disease severity. Except for this, immunization can reduce the frequency of poor outcomes (hospitalization, ICU admission, and mortality), and individuals should be made aware of the importance of becoming vaccinated as soon as possible. Keywords: COVID 19, Vaccination, Pandemic, Mortality

Impact of COVID-19 Vaccination on Women During Pregnancy and Breastfeeding

“…It was revealed that COVID-19 vaccination was successful and beneficial for lowering the severity of the condition. Similar results were reported elsewhere wherein recovery among the vaccinated mass was greater (80%) than in non-vaccinated patients (38.6%) [ 35 ]. In contrast to vaccinated patients, who experienced hospitalization ICU admission and mortality was found in a smaller number of cases, the recurrence of poor consequences in non-vaccinated patients was significantly higher.…”

Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review

“…A total of 14 studies were included to analyze the effect of age. We found no statistical difference in the age of the two groups (SMD = 0.085, 95% CI = À0.073-0.189, p = 0.388, 12 Case-control study 346 1100 ☆☆☆ ☆☆ ☆☆ 7☆ Wi 18 Case-control study 142 20 ☆☆ ☆☆ ☆☆ 6☆ Tenforde 13 Case-control study 314 1669 ☆☆☆ ☆☆ ☆☆ 7☆ Hsu 19 Case-control study 85 85 ☆☆ ☆☆ ☆☆☆ 7☆ Blanquart 20 Case-control study 724 5459 ☆☆☆ ☆☆ ☆☆ 7☆ Bollineni 21 Case-control study 14 56 ☆ ☆☆ ☆☆☆ 6☆ Marincu 22 Case-control study 62 62 ☆☆ ☆☆ ☆☆☆ 7☆ Wolff 23 Case-control study 260 507 ☆☆☆ ☆☆ ☆☆☆ 8☆ Kalligeros 24 Case-control study 91 824 ☆☆☆ ☆☆ ☆☆☆ 8☆ Fragoulis 25 Cohort study 101 60 ☆☆☆ ☆☆ ☆☆☆ 8☆ Trunfio 26 Cohort study 55 110 ☆☆☆ ☆☆ ☆☆ 7☆ Safdar 27 Cohort study 45 65 ☆☆☆ ☆☆ ☆☆☆ 8☆ Bouton 28 Cohort study 96 329 ☆☆ ☆☆ ☆☆☆ 7☆ Bosch 29 Case-control study 126 839 ☆☆ ☆☆ ☆☆☆ 7☆ Christensen 30 Case-control study 3346 13,619 ☆☆☆ ☆☆ ☆☆☆ 8☆ Yu 31 Case-control study 23 50 ☆☆☆ ☆☆ ☆☆☆ 8☆ Bayhan 32 Case-control study 38 190 ☆☆☆ ☆☆ ☆☆☆ 8☆ Kustin 33 Case-control study 396 396 ☆☆ ☆☆ ☆☆ 6☆ Toda 34 Case-control study 11 15 ☆☆☆ ☆☆ ☆☆☆ 8☆ Tian 4 Case-control study 88 41 ☆☆☆ ☆☆ ☆☆☆ 8☆ Sayed 35 Case-control study 50 70 ☆☆☆ ☆☆ ☆☆☆ 8☆ Lee 36 Case-control study 174 587 ☆☆☆ ☆☆ ☆☆☆ 8☆ Luo 37 Case-control study 484 1782 ☆☆☆ ☆☆ ☆☆ 7☆ Puhach 38 Case-control study 139 245 ☆☆ ☆☆ ☆☆ 6☆ Whittaker 39 Case-control study 716 2487 ☆☆☆ ☆☆ ☆☆☆ 8☆ Sanghavi 40 Case-control study 149 478 ☆☆☆ ☆☆ ☆☆☆ 8☆ Butt (1) 41 Case-control study 250 250 ☆☆☆ ☆☆ ☆☆☆ 8☆ Butt (2) 42 Case-control study 456 456 ☆☆☆ ☆☆ ☆☆☆ 8☆ Spiera 43 Case-control study 88 2317 ☆☆ ☆☆ ☆☆☆ 7☆ Baltas 44 Case-control study 119 476 ☆☆☆ ☆☆ ☆☆ 7☆ John 45 Case-control study 254 508 ☆☆ ☆☆ ☆☆ 6☆ Jacobson 46 Case-control study 189 471 ☆☆ ☆☆ ☆☆ 6☆ Estofolete …”